Case studies / Medical device — FDA Class II end device

Medical LSR diaphragm: 100 steam cycles without yellowing

A respiratory valve diaphragm assessed after 100 cycles of 121°C wet-heat sterilisation, where the acceptance criteria were colour and yield rather than tensile strength.

Medical device — FDA Class II end deviceLSR Medical/FoodPC-42
Result at a glance
YI ≤ 1.5
after 100 × 121°C cycles
98%
line yield, up from 82%
100 cycles
validated sterilisation exposure

Each figure is tied to a measurement, and the result section below states the conditions that produced it. Field data and accelerated aging data are labelled separately, and the disclosure at the end of the case states how the data was obtained.

Visualised

Measured, not claimed.

Schematic of the measurement behind this case: the same conditions, drawn to be read at a glance. The drawing is illustrative; the measured values are the ones stated in the result sections.

Sterilisation comparison, YI ≤ 1.5STERILISATION · 121 °C × 100 CYCLES · SCHEMATICYELLOWEDCONVENTIONAL KARSTEDTvisible yellowingYI ≤ 1.5PC-42 / PC-50 SYSTEMno visible colour shiftCUSTOMER FIELD RESULT · YIELD 82% → 98%
Sterilisation comparison schematic for an LSR medical diaphragm: 100 cycles of 121 °C wet-heat steam, conventional system on the left and the PC-42 / PC-50 system on the right. YI ≤ 1.5 and the 82 % → 98 % yield are customer field results; the swatches are illustrative.
On the line

Where this grade is used.

Representative production images of the processes these grades are specified for. The parts shown are end applications, not test data; measured values stay in the data sections above.

Clear liquid silicone rubber moulded parts in an aluminium mould
Moulded LSR parts for medical devicesValve diaphragms, seals and other liquid silicone mouldings are cured with a platinum addition system. Sterilisation and biocompatibility testing belong to the finished device, not to the catalyst.
01 / Challenge

The challenge.

A respiratory valve diaphragm had to survive repeated 121°C wet-heat sterilisation without visible colour change. With the incumbent catalyst, yield after sterilisation was 82% and rejected parts were discoloured.

The cost sits at the end of the process. The moulding work and the material are already spent before the part fails inspection, so a yield loss at sterilisation is more expensive than the same loss at moulding. Colour retention had to be solved in the formulation rather than sorted out in inspection.

Repeated steam exposure is a different test from a single cure check. A part can pass the first sterilisation and still discolour at cycle 60, which is why the case was validated over the full 100-cycle protocol instead of a short screening run.

02 / Solution

The solution.

8,000 PPM medical LSR formulation with PC-42 anti-yellowing catalyst, validated through 100 wet-heat sterilisation cycles.

The project was run as a customer-validated field case: the compound was moulded into the production part geometry and validated through the full exposure, not screened on plaques. That is the only way to connect a catalyst grade to a yield number.

The catalyst addresses colour; the inhibitor package sets the working time on the injection line. Keeping those two decisions separate is what allows the formulation to be adjusted without re-qualifying the colour result.

03 / Result

The result, and what produced it.

The numbers at the top of the page are the headline metrics from this case. The paragraphs here explain what produced them, with the test method and the exposure stated alongside.

Yellowness index stayed at or below 1.5 through 100 cycles and line yield moved from 82% to 98%. Both figures are specific to this formulation and this sterilisation protocol.

The result does not establish shelf life, biocompatibility or regulatory clearance. It states that this formulation retained colour and improved yield under this protocol.

Sterilisation validation is part-specific. A change of wall thickness, cycle profile or steam quality is a reason to repeat the colour measurement, not to rely on this result.

Test conditions and data scope

Customer field case. Yellowness index measured after 100 cycles of 121°C wet-heat sterilisation; the device is a Class II end device, and this case does not imply regulatory approval of the catalyst itself.

Customer-validated field case. The FDA Class II reference describes the end-device category only, not the catalyst.

Traceability

The grades and the application behind this case.

Every case is tied to a catalyst grade and to an application page. The grade page carries the full specification; the application page carries the process window, dosage range and inhibitor pairing for this class of part.

ModelPt concentrationViscosityRecommended dosage
PC-425,000 PPM300–500 cP0.05%–0.5% of total compound

Open a model for packaging, shelf life, features and inhibitor pairing. Where a case names more than one grade, the solution section states which one was used in the reported trial.

Application

LSR Medical/Food

Addition cure with no by-products.

Platinum-catalysed, VOC-free systems for medical tubing, respiratory valves, baby teats and bakeware.

PC-42PC-12PC-51
Next step

Run a comparable trial on your own line.

Send the part, the failure and the acceptance test. We will send evaluation samples of the grade used in this case, paired with the matching inhibitor, and confirm the starting dosage for your cure window.

Technical reply within 24 hours
Evaluation samples in 5–7 days
COA, TDS and SDS on request
Custom concentration 1,000–20,000 PPM